WO2002006247A8 - Substituierte amidoalkyl-uracile als parp-inhibitoren - Google Patents

Substituierte amidoalkyl-uracile als parp-inhibitoren

Info

Publication number
WO2002006247A8
WO2002006247A8 PCT/EP2001/007670 EP0107670W WO0206247A8 WO 2002006247 A8 WO2002006247 A8 WO 2002006247A8 EP 0107670 W EP0107670 W EP 0107670W WO 0206247 A8 WO0206247 A8 WO 0206247A8
Authority
WO
WIPO (PCT)
Prior art keywords
parp inhibitors
uracils
amidoalkyl
substituted amidoalkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/007670
Other languages
English (en)
French (fr)
Other versions
WO2002006247A1 (de
Inventor
Michael Haerter
Barbara Albrecht
Michael Gerisch
Gabriele Handke
Joachim Huetter
Axel Jensen
Thomas Krahn
Joachim Mittendorf
Felix Oehme
Karl-Heinz Schlemmer
Henning Steinhagen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to EP01947443A priority Critical patent/EP1303497A1/de
Priority to AU2001269121A priority patent/AU2001269121A1/en
Priority to CA002416036A priority patent/CA2416036A1/en
Publication of WO2002006247A1 publication Critical patent/WO2002006247A1/de
Publication of WO2002006247A8 publication Critical patent/WO2002006247A8/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Es werden neue PARP-Inhibitoren in Form von Amidoalkyl-uracil-Derivaten der Formel (I), ein Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittelwirkstoffe zur Prophylaxe und/oder Behandlung von Ischämie- und Reperfusionsschäden beschrieben.
PCT/EP2001/007670 2000-07-18 2001-07-05 Substituierte amidoalkyl-uracile als parp-inhibitoren Ceased WO2002006247A1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01947443A EP1303497A1 (de) 2000-07-18 2001-07-05 Substituierte amidoalkyl-uracile als parp-inhibitoren
AU2001269121A AU2001269121A1 (en) 2000-07-18 2001-07-05 Substituted amidoalkyl-uracils as parp inhibitors
CA002416036A CA2416036A1 (en) 2000-07-18 2001-07-05 Substituted amidoalkyl-uracils as parp inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10034801A DE10034801A1 (de) 2000-07-18 2000-07-18 Substituierte Amidoalkyl-uracile und ihre Verwendung
DE10034801.7 2000-07-18

Publications (2)

Publication Number Publication Date
WO2002006247A1 WO2002006247A1 (de) 2002-01-24
WO2002006247A8 true WO2002006247A8 (de) 2002-02-21

Family

ID=7649257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007670 Ceased WO2002006247A1 (de) 2000-07-18 2001-07-05 Substituierte amidoalkyl-uracile als parp-inhibitoren

Country Status (6)

Country Link
US (1) US6649618B2 (de)
EP (1) EP1303497A1 (de)
AU (1) AU2001269121A1 (de)
CA (1) CA2416036A1 (de)
DE (1) DE10034801A1 (de)
WO (1) WO2002006247A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10201240A1 (de) * 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
US7009052B2 (en) * 2003-03-20 2006-03-07 Warner Lambert Company Llc Sulfonamide derivatives
CA2686848A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
EP2773623B1 (de) * 2011-11-01 2020-04-29 Impact Therapeutics, Inc. 1- (arylmethyl) -5,6,7,8-tetrahydrochinazolin-2,4-dione sowie analoga und ihre verwendung
EP3332645A1 (de) 2016-12-12 2018-06-13 Bayer Cropscience AG Verwendung substituierter pyrimidindione oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1959705A1 (de) 1969-11-28 1971-06-03 Bayer Ag Verfahren zur Herstellung von Uracilderivaten
DE2126148A1 (en) 1971-05-26 1972-12-07 Farbenfabriken Bayer Ag, 5090 Leverkusen Prepn of uracil derivs - useful as plant - protection agents and their inters
DE2142317A1 (de) 1971-08-24 1973-03-01 Bayer Ag Hypnotisches mittel
JP2860689B2 (ja) * 1990-03-14 1999-02-24 第一製薬株式会社 ピリミジン誘導体
JP3264579B2 (ja) 1994-03-18 2002-03-11 扶桑薬品工業株式会社 クラミジア・トラコマチス血清型の鑑別法
GB9702701D0 (en) * 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
AU2004200A (en) 1999-01-14 2000-08-01 Meiji Seika Kaisha Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives

Also Published As

Publication number Publication date
AU2001269121A1 (en) 2002-01-30
EP1303497A1 (de) 2003-04-23
US6649618B2 (en) 2003-11-18
WO2002006247A1 (de) 2002-01-24
CA2416036A1 (en) 2002-01-24
DE10034801A1 (de) 2002-01-31
US20030022905A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
DE60236102D1 (en) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
WO2001066564A3 (en) Gamma-secretase inhibitors
WO2001047928A3 (de) Imidazo 1,3,5 triazinone und ihre verwendung
AU8765401A (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation andpharmaceutical compositions comprising them
MXPA04001889A (es) Inhibidores de la alquin-aril fosfodiesterasa-4.
MXPA05002871A (es) Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen.
TR200103493T2 (tr) Metaloproteaz önleyicileri
IL152830A0 (en) Arylmethylamine derivatives for use as tryptase inhibitors
AU2002331391A1 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
WO2001064676A3 (en) INHIBITORS OF p38-α KINASE
WO2003051275A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
WO2002051983A3 (en) Novel compounds and compositions as cathepsin inhibitors
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
WO2001051473A8 (de) 1,2-diarylbenzimidazole zur behandlung von krankungen die mit einer microglia-aktivierung assoziiert sind
CA2414311A1 (en) Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme
WO2002098850A3 (en) Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
WO2002010152A3 (de) Neue indolderivate und deren verwendung als arzneimittel
WO2002032901A3 (en) Bridged piperazine derivatives
WO2003082881A3 (en) Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
WO2002006247A8 (de) Substituierte amidoalkyl-uracile als parp-inhibitoren
PL359409A1 (en) Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity
WO2001046128A3 (en) Tryptase inhibitors
YU34604A (sh) Oligopeptidi kao inhibitori katepsina s i kompozicije koje ih sadrže
WO2000073274A3 (de) Substituierte phenylcyclohexancarbonsäureamide und ihre verwendung als adenosinaufnahme-inhibitoren
WO2001030327A3 (de) Verwendung von 2-imidazolyl-substituierten carbinolen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 04/2002 UNDER (51) AFTER "C07D403/12" ADD "C07D405/12"

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001947443

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2416036

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001947443

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP

WWR Wipo information: refused in national office

Ref document number: 2001947443

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001947443

Country of ref document: EP